

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.308; Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Roche (rituximab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arthritis Care • British Kidney Patient Association • British Lung Foundation • Kidney Research UK • Lauren Currie Twilight Foundation • Lupus UK • Muslim Council of Britain • National Kidney Federation • National Rheumatoid Arthritis Society • South Asian Health Foundation • Specialised Healthcare Alliance • Vasculitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Technologists • Association of Respiratory Nurse Specialists • British Association of Dermatologists • British Association of Skin Cancer Specialist Nurses • British Association of Urological Nurses • British Association of Urological Surgeons • British Dermatological Nursing Group • British Renal Society • British Skin Foundation • British Geriatrics Society • British Renal Society • British Society for Rheumatology • British Thoracic Society • Primary Care Respiratory Society UK 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Kidney Patients Association <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Actavis UK (azathioprine, mycophenolate) • Accord Healthcare (methotrexate, mycophenolate) • Allergen (azathioprine) • Aspen Medical Europe (azathioprine) • Baxter Healthcare (cyclophosphamide) • Dr Reddy's Laboratories (UK) (mycophenolate) • Hospira UK (methotrexate) • Medac UK (methotrexate) • Mylan UK (azathioprine, mycophenolate)

<ul style="list-style-type: none"> • Primary Care Rheumatology Society • Renal Association • Royal College of General Practitioners • Primary Care Dermatology Society • Royal College of Nursing • Renal Association • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Society for DGH Nephrologists • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Renal Pharmacy Group • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS North Staffordshire CCG • NHS Richmond CCG • Welsh Government 	<ul style="list-style-type: none"> • Novartis Pharmaceuticals (mycophenolate) • Orion Pharma (UK) (methotrexate) • Pfizer (cyclophosphamide, methotrexate) • Roche Products (mycophenolate) • Sandoz (azathioprine, cyclophosphamide, methotrexate, mycophenolate) • Teva UK (azathioprine, methotrexate, mycophenolate) • Wockhardt UK (mycophenolate) • Zentiva UK (mycophenolate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Arthritis Research UK • British Association for Lung Research • British Society for Dermatological Surgery • Chronic Pain Policy Coalition • Cochrane Airways Group • Cochrane Kidney and Transplant Group • Cochrane Musculoskeletal Group • Cochrane Vascular • Cochrane Skin Group • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Skin Research Centre • Skin Treatment and Research Trust • Thrombosis Research Institute <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

STA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.